Company intelligence / Profile preview

CureVerse

Seongbuk District, Seoul, South Koreacureverse.co.kr ↗

Ownership: Private
Employees: ~8
Development stage: Phase 1

Overview

CureVerse has developed CV-01, an oral small-molecule candidate for Alzheimer's disease that was licensed to Angelini Pharma in a $360 million deal. The company also has CV-02 in preclinical development for Multiple Sclerosis. CV-01 works by suppressing neuroinflammatory reactions through the Keap1-Nrf2 signaling pathway[3][4].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

CV-03

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Angelini Pharma SpA

Beyond the preview

Go deeper on CureVerse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CureVerse.

Explore the full profile